A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer-Reference-Cited by-同舟云学术

A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer

Published:2015-08-14 Issue:31 Volume:6 Page:32228-32243
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Dijkgraaf Eveline M.¹,Santegoets Saskia J.A.M.¹,Reyners An K.L.²,Goedemans Renske¹,Nijman Hans W.³,van Poelgeest Mariëtte I.E.⁴,van Erkel Arien R.⁵,Smit Vincent T.H.B.M.⁶,Daemen Toos A.H.H.⁷,van der Hoeven Jacobus J.M.¹,Melief Cornelis J.M.⁸,Welters Marij J.P.¹,Kroep Judith R.¹,van der Burg Sjoerd H.¹

Affiliation:

1. Department of Medical Oncology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands

2. Department of Clinical Oncology, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands

3. Department of Gynecologic Oncology, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands

4. Department of Gynecology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands

5. Department of Radiology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands

6. Department of Pathology, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands

7. Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands

8. Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2333 ZA, Leiden, The Netherlands

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer;Journal of Nanobiotechnology;2024-08-13

2. The bright side of chemistry: Exploring synthetic peptide‐based anticancer vaccines;Journal of Peptide Science;2024-04-03

3. Potential role of p53 deregulation in modulating immune responses in human malignancies: A paradigm to develop immunotherapy;Cancer Letters;2024-04

4. Pan‐cancer analyses of immunogenic cell death‐derived gene signatures: Potential biomarkers for prognosis and immunotherapy;Cancer Reports;2024-04

5. Myeloid-derived suppressor cells in cancer and cancer therapy;Nature Reviews Clinical Oncology;2024-01-08